Understanding the importance of using the right diagnostic criteria for cachexia is crucial, as it can significantly influence the health and survival of cancer patients. Maintaining good health and ...

This schematic illustration shows the major organs that are affected by and contribute to the development of pancreatic cancer cachexia. With pancreatic cancer at the center of the crosstalk network, ...

MUNICH--(BUSINESS WIRE)--CatalYm today announced new findings from its ongoing Phase 1/2a study as well as preclinical research, highlighting the therapeutic potential of its lead drug candidate, ...

Reimagining Cancer Care for Patients Experiencing Homelessness by Expanding the Traditional Oncology Team Cachexia is a systemic wasting syndrome prevalent in patients with cancer that significantly ...

Pfizer said its experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial. Patients with the ...

Please provide your email address to receive an email when new articles are posted on . Patients with cancer cachexia assigned ponsegromab gained significantly more weight than those assigned placebo.

Up to 80 percent of patients with cancer struggle with cachexia, often called wasting syndrome, which is a condition characterized by the inability to gain or maintain body weight. One of the reasons ...

Cancer cachexia is a complex metabolic syndrome characterized by the ongoing loss of skeletal muscle mass, with or without fat loss, that cannot be reversed entirely by conventional nutritional ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced ...

Study met primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at ...